What makes your innovation unique?
WINGO is an intelligent wearable for people with diabetes who suffer from diabetic sensorimotor peripheral neuropathy (DSPN). It improves mobility through focal muscle stimulation. Based on bionic principles and the 2021 Nobel Prize in Medicine, WINGO will commence clinical trials in 2025.
Advantages
• The system consists of sensors, coded information and actuators that provide feedback to the brain and forward movements to the muscles.
• It reduces the risk of amputation and is estimated to benefit over 200 million affected people.
Awards
• Horizon Europe
• EIC Accelerator Seal of Excellence – 2024
About the company
SQAIL develops scientifically based products and therapy concepts focussed on the treatment of diabetic neuropathy (DSPN). The core product WINGO improves social participation and quality of life. Offering global potential and major savings for healthcare systems, SQAIL plans to enter the market in 2025 following MDR/FDA approval.
